10-Q: Meso Numismatics Reports Increased Revenue but Continues to Face Losses and Debt Issues in Q2 2024

Meso Numismatics, Inc. reports a revenue increase for Q2 2024 but continues to struggle with net losses, substantial debt, and going concern uncertainties.

Summary

• Meso Numismatics, Inc. reported its financial results for the quarter ended June 30, 2024.
• The company experienced an increase in revenue by 119.54% to $793,329 for the three months ended June 30, 2024, compared to $361,359 for the same period in 2023.
• The increase in revenue is attributed to marketing and sales efforts, increased lead generation, and the opening of the Cancun facility.
• However, the company continues to face net losses, reporting a net loss of $2,076,620 for the three months ended June 30, 2024, compared to a net loss of $2,030,223 for the same period in 2023.
• Operating expenses increased by 8.21% to $740,865 for the three months ended June 30, 2024.
• Interest expense remains high at $1,861,931 for the quarter.
• The company has a significant accumulated deficit of $66,027,771 and a working capital deficit of $25,730,147 as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is pursuing debt restructuring and seeking additional financing to address its financial challenges.
• The company is in default on several promissory notes.
• The company's ability to continue operations depends on raising capital and achieving sufficient funding from operations.

Sentiment

Score: 3

Explanation: The sentiment is low due to continued losses, high debt, and going concern uncertainties, despite revenue growth.

Positives

• Revenue increased by 119.54% for the three months ended June 30, 2024, indicating growth in the business.
• The opening of the Cancun facility has contributed to increased sales.
• The company is actively pursuing debt restructuring to alleviate financial pressure.

Negatives

• The company continues to experience net losses, with a net loss of $2,076,620 for the three months ended June 30, 2024.
• The company has a substantial accumulated deficit of $66,027,771 and a working capital deficit of $25,730,147.
• The company is in default on several promissory notes, indicating financial distress.
• High interest expense continues to burden the company's financials.
• There are material weaknesses in internal control over financial reporting.

Risks

• The company faces substantial doubt about its ability to continue as a going concern.
• Failure to obtain adequate financing could impair the implementation of the business plan and lead to business failure.
• The company is exposed to risks related to outstanding secured and unsecured loans, certain of which are in default.
• Legislative or regulatory changes concerning regenerative medicine and therapies could impact the business.
• Competition and cybersecurity concerns pose additional risks.

Future Outlook

The company expects revenues to increase in future quarters due to ongoing marketing and brand awareness campaigns, training seminars, and expansion efforts. The company also anticipates an increase in operating expenses as it implements its business plan and expands operations. The company's ability to continue operations is dependent on raising capital and achieving sufficient funding from operations.

Management Comments

• Since the acquisition of Global Stem Cell Group (GSCG) in August of 2021, our focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry.
• We believe stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management.
• During 2024, we plan to continue to add manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever.

Industry Context

The company operates in the regenerative medicine industry, which is experiencing growth as patients seek alternative treatments. The company's strategy involves providing products, training, and services to doctors in this field. The company faces competition and regulatory risks within this industry.

Comparison to Industry Standards

• It's difficult to directly compare Meso Numismatics to industry standards due to its unique combination of numismatics and stem cell therapy businesses.
• However, in the stem cell therapy industry, companies like Celgene (now part of Bristol Myers Squibb) and Mesoblast have faced similar challenges in navigating regulatory hurdles and achieving profitability.
• Compared to these larger companies, Meso Numismatics is a smaller player with limited resources, making its financial situation more precarious.
• The company's reliance on debt financing is also a concern, as many biotech companies rely on equity financing to fund research and development.

Related Party Transactions

• Dave Christensen, the CEO, receives compensation monthly based on an annual rate of $90,000.
• Amounts paid to Enterprise Technology Consulting, a company 100% owned by Dave Christensen, CEO, for consulting services during the period ended June 30, 2024 and the year ended December 31, 2023 were $45,000 and $90,000, respectively.
• Benito Novas' brother, sister, and nephew provide marketing/administrative and training/R&D services to Global Stem Cells Group and were paid $122,107 in the aggregate as consultants during the six months ended June 30, 2024.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises capital through equity offerings.
• Employees face uncertainty due to the company's going concern issues.
• Creditors face the risk of non-payment due to the company's financial distress.

Next Steps

• The company plans to continue implementing its business plan.
• The company intends to seek additional financing through debt and/or equity markets.
• The company plans to take remedial action to address material weaknesses in internal control over financial reporting during the fiscal year ended December 31, 2024.

Key Dates

Keywords

Meso Numismatics, Global Stem Cells Group, Stem Cell Therapy, Regenerative Medicine, Financial Results, Revenue, Net Loss, Debt, Going Concern, Promissory Notes, Default, Financial Statements